Matt O'Brien
Stock Analyst at Piper Sandler
(2.50)
# 2,275
Out of 4,712 analysts
172
Total ratings
49.65%
Success rate
-2.01%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
TMDX TransMedics Group | Maintains: Overweight | $110 → $90 | $62.60 | +43.77% | 9 | Dec 11, 2024 | |
PEN Penumbra | Maintains: Overweight | $235 → $250 | $240.54 | +3.93% | 12 | Nov 20, 2024 | |
RCEL AVITA Medical | Reiterates: Neutral | $9 → $12 | $13.17 | -8.88% | 7 | Nov 8, 2024 | |
SGHT Sight Sciences | Reiterates: Neutral | $6 → $5.5 | $3.61 | +52.35% | 6 | Nov 8, 2024 | |
TELA TELA Bio | Maintains: Overweight | $8 → $5 | $2.92 | +71.23% | 5 | Nov 8, 2024 | |
GMED Globus Medical | Maintains: Overweight | $80 → $100 | $84.42 | +18.46% | 11 | Nov 6, 2024 | |
CVRX CVRx, Inc. | Reiterates: Overweight | $13 → $16 | $13.62 | +17.47% | 7 | Oct 30, 2024 | |
SYK Stryker | Reiterates: Overweight | $380 → $420 | $369.42 | +13.69% | 12 | Oct 30, 2024 | |
ITGR Integer Holdings | Reiterates: Overweight | $125 → $140 | $135.88 | +3.03% | 2 | Oct 25, 2024 | |
PRCT PROCEPT BioRobotics | Reiterates: Overweight | $75 | $83.53 | -10.21% | 3 | Oct 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $285 | $265.68 | +7.27% | 7 | Sep 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $80.57 | +11.70% | 10 | Aug 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $81.60 | +10.29% | 9 | Aug 21, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $1 | $0.32 | +213.58% | 12 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $10.35 | +15.94% | 4 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 → $55 | $37.37 | +47.18% | 7 | Aug 2, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $12 | $9.33 | +28.62% | 1 | Aug 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $140 | $152.67 | -8.30% | 8 | Aug 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $71.23 | +12.31% | 12 | Aug 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $40 | $30.75 | +30.08% | 2 | Jul 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $205 → $245 | $180.14 | +36.01% | 4 | Jul 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $40 | $24.60 | +62.60% | 6 | May 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.84 | +80.64% | 1 | Mar 28, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $40 | $23.38 | +71.09% | 1 | Mar 27, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $5.29 | -43.29% | 2 | Nov 10, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.60 | +181.25% | 2 | Aug 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $62 | $91.45 | -32.20% | 2 | Jul 6, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $107.25 | - | 2 | Mar 10, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.77 | +214.47% | 1 | Feb 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $92.61 | +17.43% | 1 | Feb 11, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $8.32 | +118.51% | 2 | Jan 29, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $29.30 | +173.04% | 1 | Jan 29, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.99 | +200.75% | 1 | Jun 24, 2020 |
TransMedics Group
Dec 11, 2024
Maintains: Overweight
Price Target: $110 → $90
Current: $62.60
Upside: +43.77%
Penumbra
Nov 20, 2024
Maintains: Overweight
Price Target: $235 → $250
Current: $240.54
Upside: +3.93%
AVITA Medical
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $13.17
Upside: -8.88%
Sight Sciences
Nov 8, 2024
Reiterates: Neutral
Price Target: $6 → $5.5
Current: $3.61
Upside: +52.35%
TELA Bio
Nov 8, 2024
Maintains: Overweight
Price Target: $8 → $5
Current: $2.92
Upside: +71.23%
Globus Medical
Nov 6, 2024
Maintains: Overweight
Price Target: $80 → $100
Current: $84.42
Upside: +18.46%
CVRx, Inc.
Oct 30, 2024
Reiterates: Overweight
Price Target: $13 → $16
Current: $13.62
Upside: +17.47%
Stryker
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $369.42
Upside: +13.69%
Integer Holdings
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $135.88
Upside: +3.03%
PROCEPT BioRobotics
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $83.53
Upside: -10.21%
Sep 17, 2024
Maintains: Overweight
Price Target: $230 → $285
Current: $265.68
Upside: +7.27%
Aug 26, 2024
Reiterates: Overweight
Price Target: $90
Current: $80.57
Upside: +11.70%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $81.60
Upside: +10.29%
Aug 9, 2024
Reiterates: Neutral
Price Target: $3 → $1
Current: $0.32
Upside: +213.58%
Aug 9, 2024
Reiterates: Overweight
Price Target: $15 → $12
Current: $10.35
Upside: +15.94%
Aug 2, 2024
Reiterates: Overweight
Price Target: $50 → $55
Current: $37.37
Upside: +47.18%
Aug 1, 2024
Maintains: Overweight
Price Target: $17 → $12
Current: $9.33
Upside: +28.62%
Aug 1, 2024
Maintains: Overweight
Price Target: $110 → $140
Current: $152.67
Upside: -8.30%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $71.23
Upside: +12.31%
Jul 31, 2024
Maintains: Overweight
Price Target: $65 → $40
Current: $30.75
Upside: +30.08%
Jul 1, 2024
Upgrades: Overweight
Price Target: $205 → $245
Current: $180.14
Upside: +36.01%
May 8, 2024
Maintains: Neutral
Price Target: $33 → $40
Current: $24.60
Upside: +62.60%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $13.84
Upside: +80.64%
Mar 27, 2024
Reiterates: Overweight
Price Target: $40
Current: $23.38
Upside: +71.09%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $5.29
Upside: -43.29%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.60
Upside: +181.25%
Jul 6, 2023
Maintains: Overweight
Price Target: $58 → $62
Current: $91.45
Upside: -32.20%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $107.25
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.77
Upside: +214.47%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $92.61
Upside: +17.43%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $8.32
Upside: +118.51%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $29.30
Upside: +173.04%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.99
Upside: +200.75%